FCGR3A and cancer: Then, guided by recent findings indicating that some CD16A polymorphisms predict the therapeutic effectiveness of cetuximab in EGFR+ cancer patients [49], we found that only CD16A-48H gene variant is involved, being more associated with CRC patients and advanced stages of CRC.